Vaccine and Vector Safety

Charles River’s capabilities include vaccine and vector safety studies in multiple species. These studies provide not only efficacy and safety testing data for vaccines and other anti-infective agents, but also support for pharmacologic/toxicologic evaluation of gene therapy constructs. We design and perform studies in CDC-approved quarantine facilities with BSL-2 ratings to fulfill your preclinical regulatory needs in a GLP-compliant environment.

Experience

• Viral, parasitic, and bacterial vaccines
• Both subunit and live vaccines
• Various small molecule anti-infectious agents and immune enhancers
• DNA and viral vectors
• Multiple routes of vector/vaccine administration

Neurovirulence Safety Testing

Our scientists also offer neurovirulence safety testing, since many immunogenic attenuated vaccines are known to possess residual neurovirulence following introduction to the brain. Using direct intracerebral or intrathalamic injection, we conduct these studies to assess the safety of new vaccines and to evaluate the continued safety of established vaccine seed stocks following directed modification or changes in the manufacturing process.

Testing Design Features

• Intracerebral or intrathalamic dosing
• Clinical pathology analyses
• Viral titer and antiviral antibody analyses
• Anatomical pathology evaluation
• Vector biodistribution by quantitative PCR

Experience

• Flavivirus
• Poxvirus
• Paramyxovirus
• Rhabdovirus

What's New

All news items

 Charles River Home | Careers | Humane Care | Events | News Room | Investor Relations | Site Index | Contact